MCID: DBT008
MIFTS: 47

Diabetic Angiopathy

Categories: Cardiovascular diseases

Aliases & Classifications for Diabetic Angiopathy

MalaCards integrated aliases for Diabetic Angiopathy:

Name: Diabetic Angiopathy 12 76 15
Diabetic Angiopathies 55 44 73
Diabetic Vascular Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11713
MeSH 44 D003925
NCIt 50 C35610
UMLS 73 C0011875

Summaries for Diabetic Angiopathy

MalaCards based summary : Diabetic Angiopathy, also known as diabetic angiopathies, is related to vasculitis and vascular disease. An important gene associated with Diabetic Angiopathy is IGFBP7 (Insulin Like Growth Factor Binding Protein 7), and among its related pathways/superpathways are Glucose / Energy Metabolism and Longevity regulating pathway. The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and bone, and related phenotypes are cellular and cardiovascular system

Wikipedia : 76 Diabetic angiopathy is a form of angiopathy associated with diabetic complications. While not exclusive,... more...

Related Diseases for Diabetic Angiopathy

Diseases related to Diabetic Angiopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Related Disease Score Top Affiliating Genes
1 vasculitis 28.3 CCL2 SELE THBD VWF
2 vascular disease 23.8 AGER CAT CCL2 EDN1 INS MTHFR
3 intracranial thrombosis 10.5 MTHFR VWF
4 osteoporotic fracture 10.5 MTHFR TNFRSF11B
5 unilateral absence of a pulmonary artery 10.5 THBD VWF
6 retinal vascular occlusion 10.5 CCL2 MTHFR
7 diabetic encephalopathy 10.4 CAT INS
8 type 1 diabetes mellitus 10 10.4 CAT SOD2
9 diabetic polyneuropathy 10.3 AGER SOD2
10 raynaud disease 10.3 EDN1 VWF
11 angina pectoris 10.3 EDN1 VWF
12 marantic endocarditis 10.3 MTHFR THBD
13 mesangial proliferative glomerulonephritis 10.2 CCL2 EDN1
14 spotted fever 10.2 THBD VWF
15 myocardial stunning 10.1 CAT EDN1
16 critical limb ischemia 10.1 SELE VWF
17 scleritis 10.0 CCL2 SELE
18 uremia 10.0 INS TNFRSF11B VWF
19 blood coagulation disease 10.0 MTHFR THBD VWF
20 thrombophilia due to activated protein c resistance 10.0 MTHFR THBD VWF
21 thrombophilia due to thrombin defect 10.0 MTHFR THBD VWF
22 neuropathy 10.0
23 thrombosis 10.0 MTHFR THBD VWF
24 idiopathic edema 9.9 EDN1 INS
25 thrombophilia 9.9 MTHFR THBD VWF
26 hepatic vascular disease 9.9 EDN1 MTHFR
27 aspirin resistance 9.9
28 type i 9.9
29 endotheliitis 9.9
30 buerger disease 9.9 MTHFR SELE
31 renovascular hypertension 9.9 CAT EDN1
32 placental abruption 9.8 MTHFR THBD
33 dengue shock syndrome 9.8 CCL2 THBD
34 boutonneuse fever 9.8 SELE THBD
35 stroke, ischemic 9.8 MTHFR THBD VWF
36 eisenmenger syndrome 9.8 EDN1 THBD VWF
37 raynaud phenomenon 9.8 EDN1 THBD VWF
38 chronic active epstein-barr virus infection 9.8 SELE THBD
39 collagen disease 9.7 EDN1 THBD VWF
40 diabetes mellitus 9.7
41 hyperglycemia 9.7
42 pancreatitis 9.7
43 thyroiditis 9.7
44 apnea, obstructive sleep 9.7 EDN1 INS
45 nephrosclerosis 9.7 CCL2 MTHFR
46 tetralogy of fallot 9.7 CAT EDN1 MTHFR
47 urinary system disease 9.7 CCL2 EDN1 INS
48 shwartzman phenomenon 9.7 SELE THBD
49 chronic kidney failure 9.6 EDN1 INS TNFRSF11B
50 eclampsia 9.6 EDN1 MTHFR THBD

Graphical network of the top 20 diseases related to Diabetic Angiopathy:



Diseases related to Diabetic Angiopathy

Symptoms & Phenotypes for Diabetic Angiopathy

MGI Mouse Phenotypes related to Diabetic Angiopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 VWF SELE AGER CAT SOD2 THBD
2 cardiovascular system MP:0005385 10.01 VWF SELE AGER SOD2 EDN1 THBD
3 growth/size/body region MP:0005378 9.97 MTHFR SELE AGER SOD2 EDN1 IGFBP7
4 homeostasis/metabolism MP:0005376 9.91 MTHFR SELE AGER CAT SOD2 EDN1
5 immune system MP:0005387 9.76 SELE AGER CCL2 SOD2 THBD INS
6 integument MP:0010771 9.5 MTHFR SELE AGER SOD2 IGFBP7 THBD
7 mortality/aging MP:0010768 9.28 TNFRSF11B MTHFR SELE CAT SOD2 EDN1

Drugs & Therapeutics for Diabetic Angiopathy

Drugs for Diabetic Angiopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 449)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
3
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
4
Aztreonam Approved Phase 4 78110-38-0 5362041 5742832
5
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
6
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
7
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
8
Metronidazole Approved Phase 4 443-48-1 4173
9
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
10
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
11
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
12
Fenofibrate Approved Phase 4,Phase 3 49562-28-9 3339
13
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
14
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
15
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
16
Acarbose Approved, Investigational Phase 4,Early Phase 1 56180-94-0 441184
17
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
18
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 85721-33-1 2764
19
Sulfamethoxazole Approved Phase 4,Not Applicable 723-46-6 5329
20
Trimethoprim Approved, Vet_approved Phase 4,Not Applicable 738-70-5 5578
21
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 7440-66-6 23994
22
Alginic acid Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 9005-32-7
23
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 9552079 2713
24
Latanoprost Approved, Investigational Phase 4,Not Applicable 130209-82-4 5282380 5311221
25
Petrolatum Approved, Investigational Phase 4 8009-03-8
26
Dipivefrin Approved Phase 4 52365-63-6 3105
27
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
28
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
29
Cefoxitin Approved Phase 4 35607-66-0 441199
30
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
31
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 564-25-0 54671203
32
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
33
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
34
Insulin Glargine Approved Phase 4,Early Phase 1 160337-95-1
35
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
36
Sulbactam Approved Phase 4 68373-14-8
37 Sultamicillin Approved, Investigational Phase 4 76497-13-7
38
Temazepam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 846-50-4 5391
39
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
40
Vancomycin Approved Phase 4,Phase 3 1404-90-6 441141 14969
41
Allopurinol Approved Phase 4 315-30-0 2094
42
Saxagliptin Approved Phase 4 361442-04-8 11243969
43
Empagliflozin Approved Phase 4 864070-44-0
44
Glimepiride Approved Phase 4 93479-97-1 3476
45
Daptomycin Approved, Investigational Phase 4,Phase 3 103060-53-3 16129629
46
Dimenhydrinate Approved Phase 4 523-87-5 441281
47
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
48
Thrombin Approved, Investigational Phase 4,Not Applicable
49
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 862)
# Name Status NCT ID Phase Drugs
1 Maggot Debridement Therapy Versus Conventional Dressing Therapy to Treat Diabetic Foot Ulcers Unknown status NCT02816749 Phase 4
2 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
3 A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers Unknown status NCT02081352 Phase 4
4 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
5 Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4 Garamycin Sponge (Gentamicin-Collagen sponge);Systemic Antibiotic
6 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
7 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
8 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
9 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
10 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
11 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
12 Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
13 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
14 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
15 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
16 Ranibizumab in Diabetic Vitrectomy Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
17 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
18 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
19 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
20 Diabetic Foot Ulcer Study on Topical Interventions Completed NCT02577900 Phase 4
21 GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds Completed NCT02260609 Phase 4
22 Diabetic Foot Ulcer. Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water Completed NCT02097615 Phase 4
23 GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers Completed NCT02675855 Phase 4
24 Use of Santyl in Diabetic Foot Ulcers Completed NCT02581488 Phase 4
25 LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers Completed NCT02224742 Phase 4
26 Santyl vs. Sharp Debridement of Diabetic Foot Wounds Completed NCT01056198 Phase 4 Santyl
27 Santyl Applications to Diabetic Foot Ulcers Completed NCT02111291 Phase 4
28 TITLE: An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended Completed NCT01964521 Phase 4
29 Study of Oasis Ultra in Diabetic Foot Ulcers Completed NCT01835379 Phase 4
30 Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers Completed NCT01596920 Phase 4
31 Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) Completed NCT01594281 Phase 4 Ranibizumab
32 LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers Completed NCT01454401 Phase 4
33 Using Santyl on Diabetic Foot Ulcers Completed NCT01408277 Phase 4
34 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
35 Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema Completed NCT02366468 Phase 4 0.5 mg ranibizumab;0.5 mg ranibizumab
36 Wound Edge Changes Following Treatment With Santyl Completed NCT01197898 Phase 4
37 Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers Completed NCT01143727 Phase 4 Santyl;Tegaderm Hydrogel
38 A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers Completed NCT01143714 Phase 4 Santyl
39 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Completed NCT02249897 Phase 4 CHOLESTYRAMINE
40 Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot Completed NCT00224796 Phase 4
41 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
42 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
43 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
44 Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers Completed NCT00770939 Phase 4
45 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
46 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab
47 OASIS Wound Matrix (Oasis) Mechanism of Action Completed NCT00570141 Phase 4
48 Effect of the Adjunctive IVB Before PRP Completed NCT01504724 Phase 4 bevacizumab
49 Study Comparing VERSAJET With Conventional Surgical Procedures in the Removal of Unhealthy Tissue From Lower Limb Ulcers Completed NCT00521027 Phase 4
50 Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation Completed NCT01223612 Phase 4 Ranibizumab

Search NIH Clinical Center for Diabetic Angiopathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: diabetic angiopathies

Genetic Tests for Diabetic Angiopathy

Anatomical Context for Diabetic Angiopathy

MalaCards organs/tissues related to Diabetic Angiopathy:

41
Eye, Skin, Bone, Bone Marrow, Endothelial, Testes, Retina

Publications for Diabetic Angiopathy

Articles related to Diabetic Angiopathy:

(show top 50) (show all 98)
# Title Authors Year
1
MicroRNA-216b actively modulates diabetic angiopathy through inverse regulation on FZD5. ( 29477872 )
2018
2
Redox Status of I^2GPI in Different Stages of Diabetic Angiopathy. ( 27818568 )
2016
3
[SMOKING AS A TRIGGER FACTOR IN THE DEVELOPMENT OF DIABETIC ANGIOPATHY OF LOWER EXTREMITIES IN MEN WITH METHYLENETETRAHYDROFOLATEREDUCTASE 677TT GENOTYPE]. ( 26596059 )
2015
4
Is the advancement of diabetic angiopathy evaluated as ankle-brachial index directly associated with current glycaemic control? ( 23020057 )
2012
5
Diabetic angiopathy and angiogenic defects. ( 22853690 )
2012
6
Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. ( 22142668 )
2012
7
Diabetic angiopathy. ( 22616224 )
2011
8
Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. ( 20098449 )
2010
9
Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. ( 20022399 )
2010
10
Macrophage foam cell formation is augmented in serum from patients with diabetic angiopathy. ( 19939487 )
2010
11
Peroxynitrite-induced nitration of cyclooxygenase-2 and inducible nitric oxide synthase promotes their binding in diabetic angiopathy. ( 20607198 )
2010
12
Diabetes in motion in the year of the child. Meeting Highlights - 33rd Annual ISPAD Meeting, September 26-29, 2007, Berlin, Germany - 5th Symposium on Diabetic Angiopathy in Children, September 30, 2007, Berlin, Germany. ( 18211630 )
2008
13
Oxidative stress-responsive transcription factor ATF3 potentially mediates diabetic angiopathy. ( 16428460 )
2006
14
Diabetic angiopathy: new experimental and clinical aspects. ( 15918103 )
2005
15
Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. ( 15983321 )
2005
16
Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects. ( 15270792 )
2004
17
The role of nitric oxide in the development of diabetic angiopathy. ( 15156413 )
2004
18
Aspirin resistance and diabetic angiopathy: back to the future. ( 15115664 )
2004
19
Pathophysiological mechanisms of diabetic angiopathy. ( 12623164 )
2003
20
[Growth hormone, insulin-like growth factor and insulin-like growth factor binding protein in young type I diabetes patients with the onset of diabetic angiopathy]. ( 12868196 )
2003
21
Monocyte adhesion in diabetic angiopathy: effects of free-radical scavenging. ( 12623165 )
2003
22
Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. ( 12429856 )
2002
23
The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. ( 11674859 )
2001
24
Advanced glycation end products, their receptors and diabetic angiopathy. ( 11694852 )
2001
25
Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. ( 11004428 )
2000
26
Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. ( 10809802 )
2000
27
Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. ( 10651746 )
2000
28
Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. ( 10773002 )
2000
29
Advanced glycation end products in adolescents and young adults with diabetic angiopathy. ( 10955941 )
2000
30
Growth hormone, IGF-I and diabetic angiopathy revisited. ( 10651747 )
2000
31
[Pathophysiologic aspects of diabetic angiopathy]. ( 10421989 )
1999
32
Von Willebrand factor in diabetic angiopathy. ( 9805643 )
1998
33
Molecular mechanisms of diabetic angiopathy--clues for innovative therapeutic interventions. ( 9676989 )
1998
34
Quality Control of Diabetes Care and Chronic Complications in Young People after St. Vincent and Kos. Proceedings of the 4th International Workshop Diabetic Angiopathy in Children. Berlin, Germany, September 4-6, 1997. ( 9742011 )
1998
35
Urinary free cortisol and its nyctohemeral variation in adolescents and young adults with IDDM: relation to endothelin 1 and indices of diabetic angiopathy. ( 11517960 )
1998
36
Controversies on the pathogenesis of diabetic angiopathy: which treatment for normotensive adolescents with microalbuminuria and type 1 diabetes? ( 9642665 )
1998
37
[Effects of xenotransplantation of pancreatic islet cells on immunological state of patients with diabetic angiopathies]. ( 9511343 )
1997
38
Diabetic angiopathy in children. ( 9455928 )
1997
39
Endothelial dysfunction and pathogenesis of diabetic angiopathy. ( 9217873 )
1997
40
Diabetic angiopathy: tracking down the culprits. ( 8807468 )
1996
41
[The thromboxane-synthesis inhibitor Ibustrin in the treatment of diabetic angiopathies]. ( 9026936 )
1996
42
The role of hyperglycemia and hyperinsulinemia in the pathogenesis of diabetic angiopathy. ( 8905209 )
1996
43
Prostacyclin-stimulating factor, novel protein, and diabetic angiopathy. ( 8674874 )
1996
44
Enhanced expression of platelet-derived growth factor-beta receptor by high glucose. Involvement of platelet-derived growth factor in diabetic angiopathy. ( 8603774 )
1996
45
[The medical effect of magnetic-laser therapy in patients with diabetic angiopathies of the lower extremities]. ( 9138797 )
1996
46
[The results of a comparative study of the lipid peroxidation processes and of the malondialdehyde level of the blood cells in patients with diabetic angiopathies and during insulin therapy]. ( 7863440 )
1994
47
Endothelial dysfunction and diabetic angiopathy. ( 7867890 )
1994
48
[Activity of membrane-bound protein kinase C and ATPase in erythrocytes in diabetic angiopathy]. ( 8058653 )
1993
49
Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double blind trial versus placebo. ( 1644013 )
1992
50
Cell-cell interactions in diabetic angiopathy. ( 1396014 )
1992

Variations for Diabetic Angiopathy

Expression for Diabetic Angiopathy

Search GEO for disease gene expression data for Diabetic Angiopathy.

Pathways for Diabetic Angiopathy

GO Terms for Diabetic Angiopathy

Cellular components related to Diabetic Angiopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 AGER CAT CCL2 EDN1 IGFBP7 INS
2 extracellular space GO:0005615 9.23 CAT CCL2 EDN1 IGFBP7 INS SELE
3 Weibel-Palade body GO:0033093 9.16 EDN1 VWF

Biological processes related to Diabetic Angiopathy according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.85 CCL2 IGFBP7 SELE VWF
2 regulation of signaling receptor activity GO:0010469 9.76 CCL2 EDN1 INS TNFRSF11B
3 inflammatory response GO:0006954 9.71 AGER CCL2 SELE TNFRSF11B
4 positive regulation of cell migration GO:0030335 9.69 EDN1 INS SOD2
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.61 AGER CAT INS
6 response to drug GO:0042493 9.56 CAT EDN1 MTHFR TNFRSF11B
7 positive regulation of JUN kinase activity GO:0043507 9.54 AGER EDN1
8 response to amino acid GO:0043200 9.52 EDN1 MTHFR
9 response to interleukin-1 GO:0070555 9.49 MTHFR SELE
10 positive regulation of mitotic nuclear division GO:0045840 9.48 EDN1 INS
11 negative regulation of blood coagulation GO:0030195 9.37 EDN1 THBD
12 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.32 INS SOD2
13 response to lipopolysaccharide GO:0032496 9.26 EDN1 SELE THBD TNFRSF11B
14 response to ozone GO:0010193 9.16 CAT EDN1
15 response to hypoxia GO:0001666 8.92 AGER CAT EDN1 MTHFR

Molecular functions related to Diabetic Angiopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADP binding GO:0050661 9.16 CAT MTHFR
2 cytokine activity GO:0005125 9.13 CCL2 EDN1 TNFRSF11B
3 signaling receptor activity GO:0038023 8.8 AGER THBD TNFRSF11B

Sources for Diabetic Angiopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....